Repurposing Therapeutics for the Wuhan Coronavirus nCov-2019: Supercomputer-Based Docking to the Viral S Protein and Human ACE2 Interface

20 February 2020, Version 1
This content is a preprint and has not undergone peer review at the time of posting.


The novel Wuhan coronavirus (nCov-2019) has been sequenced, and the virus shares substantial similarity with SARS-CoV. Here, using a computational model of the spike protein (S-protein) nCov-2019 interacting with the human ACE2 receptor, we make use of the world's most powerful supercomputer, SUMMIT, to enact an ensemble docking virtual high-throughput screening campaign and identify small-molecules which may be repurposed to disrupt host-virus interactions. A ranked list of compounds is given that can be tested experimentally.


nCov2019, nCov-2019, COVID2019, Drug Repurposing, Docking

Supplementary materials



Comments are not moderated before they are posted, but they can be removed by the site moderators if they are found to be in contravention of our Commenting Policy [opens in a new tab] - please read this policy before you post. Comments should be used for scholarly discussion of the content in question. You can find more information about how to use the commenting feature here [opens in a new tab] .
This site is protected by reCAPTCHA and the Google Privacy Policy [opens in a new tab] and Terms of Service [opens in a new tab] apply.
Comment number 1, Jay Peppe: Nov 13, 2023, 00:01

Where are we on this? What company(ies) pursuing Supercomputer evaluation? Thank you. [email protected]